FAQs & How to use this site
Home | About Us | Contact Us
The Front Line


The Front Line: Charles D. Blanke, MD, SWOG Chair

PREVIOUS POSTS November 2017

October 2017 September 2017 August 2017 July 2017 June 2017 May 2017 April 2017 March 2017 February 2017 January 2017 December 2016 November 2016 October 2016 September 2016 August 2016 July 2016 JUNE 2016 MAY 2016 APRIL 2016 MARCH 2016 FEB 2016 JAN 2016 DEC 2015 NOV 2015 OCT 2015 SEP 2015 AUG 2015 JUL 2015 JUN 2015 MAY 2015 APR 2015 MAR 2015 FEB 2015 JAN 2015 DEC 2014 NOV 2014 OCT 2014 SEP 2014 AUG 2014 JUL 2014 JUN 2014 MAY 2014 APR 2014 MAR 2014 FEB 2014 JAN 2014 DEC 2013 NOV 2013 OCT 2013 SEP 2013 AUG 2013 JUL 2013

Red-Hot Research in Bladder Cancer

May 19, 2017 - This week, at the American Urological Association meeting in Boston, Dr. Edward Messing presented SWOG study results that could potentially change practice.

Post-operative instillation of the bladder with gemcitabine reduces the chances that a resected tumor will return. Canadian and European clinical trials had already proven this true, and now Messing and his S0337 team have done the same here in the U.S. The impact of this simple, post-surgical step is significant: The S0337 team saw a 34 percent reduction in risk of recurrence in patients receiving gemcitabine. This is a “big deal,” Messing notes in a press release because the low-grade, non-muscle invasive form of bladder cancer they were treating recurs frequently – causing anxiety and pain and costing time and money for thousands of people a year.

S0337 is classic SWOG. The study isn’t testing a potentially lucrative new drug, but putting to the test a change in medical practice that could benefit significant numbers of patients. It is the type of publicly-funded research the cooperative groups were created to perform. S0337 is an exemplar of something else – SWOG’s red-hot bladder cancer portfolio.

We have several important bladder trials underway:

  • S1011, a Phase III surgical trial led by Dr. Seth Lerner, is comparing the effects of performing a standard lymph node removal against a more extensive removal during surgery for muscle invasive bladder cancer. Experts in bladder cancer are uncertain if a more extensive operation, which may carry a high risk of complications, will reduce disease recurrence and progression. Regardless of the study’s result, it will establish a new standard of care.
  • S1605, a Phase II immunotherapy registration trial led by Drs. Peter Black and Parminder Singh, is testing the new FDA-approved atezolizumab in patients who don’t respond to BCG treatment, to see if the drug affects tumors within the bladder, reduces recurrence, and potentially allows the patient to avoid cystectomy. S1605 is the first NCI-funded immune checkpoint inhibitor trial for non-muscle invasive bladder cancer – and it was just featured in the ASCO Post.
  • S1314, a Phase II chemotherapy trial led by Dr. Thomas Flaig, is studying whether a patient with bladder cancer’s gene expression can predict response to two standard chemotherapy regimens. Results could help physicians decide which patients benefit most from chemotherapy, and which kind, before moving on to surgery or radiation. This would help some patients receive the best treatment and avoid expensive, toxic chemo that may not work well for their specific disease state.
  • S1602, a Phase III randomized immunotherapy trial led by Dr. Robert Svatek, is comparing the effects of two different strains of BCG – Tokyo and TICE – on cancer recurrence. Another study objective is to determine whether “priming” patients with an SQ injection of the Tokyo strain prior to intravesical treatment improves outcomes. Because there are occasional shortages of the TICE strain of BCG, results could open up another source of this mainstay drug.
Bladder cancer is the sixth most commonly diagnosed cancer in the U.S., and the third most common among men. It’s finally seeing a surge in drug development and research, and it’s gratifying that SWOG is playing a key role in that discovery boom.

Dr. Ian Thompson and advocate Rick Bangs deserve major credit for the great crop of bladder trials we’ve got going. Indeed, the genitourinary committee as a whole is seeing continued success. For example, GU’s other advocate, Tony Crispino, is third author on the new AUA clinically-localized prostate cancer guideline. Hats off to Ian and to all GU advocates and investigators. They are helping SWOG make a big difference.

The San Antonio Breast Cancer Symposium (SABCS) abstract submission deadline is coming up. Please submit your abstracts to SWOG publications manager Pat Arlauskas by June 5 at arlauskp@ohsu.edu for processing.

SWOG Logo Disclaimer | Copyright ©1999-2017 SWOG. All rights reserved.
Design and Hosting by nuMedia
SWOG is FISMA CertifiedSWOG is FISMA Certified